Merged technologies seen as future of glaucoma management
Click Here to Manage Email Alerts
New surgical options, novel therapeutics and the merging of technologies will continue to define the future of glaucoma management, according to George A. Cioffi, MD, keynote speaker at the virtual Glaucoma 360 New Horizons Forum.
“We need implantable or injectable sustained-release drugs, we need better, longer-lasting agents, and we’ve had some of those,” Cioffi said.
For example, long-acting latanoprostene bunod and netarsudil products have been developed.
“We even just recently got the first injectable. It took longer than most of us thought it would, but ... going forward, we have great implantable and injectable agents,” Cioffi said.
In addition to therapeutics, minimally invasive glaucoma surgery options have grown in recent years.
“This modality of lowering pressure has great promise,” Cioffi said. “The explosion and all the innovation that has gone on in this space will not be for naught.”
There remains great potential for merged technologies in the future, Cioffi said.
A system using genetically modified stem cells to deliver an agent over time, such as the NT-501 ciliary neurotrophic factor implant (Neurotech), could provide avenues for the marriage of various drug delivery systems, Cioffi said.
“I think what is going to happen is that we are going to further marry MIGS, delivery systems and these drugs, and probably even genetically modified stem cells and such, so that we continue to have better options for our patients,” Cioffi said.
Collapse
Cioffi GA. Glaucoma: What predictions came true? Presented at: Glaucoma 360 New Horizons Forum; Jan. 30, 2021 (virtual meeting).
Read more about
Click Here to Manage Email Alerts